FENC vs. CHRS, BDTX, MGX, STRO, IVVD, ADVM, GLUE, ELEV, CMPX, and PSTX
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Coherus BioSciences (CHRS), Black Diamond Therapeutics (BDTX), Metagenomi (MGX), Sutro Biopharma (STRO), Invivyd (IVVD), Adverum Biotechnologies (ADVM), Monte Rosa Therapeutics (GLUE), Elevation Oncology (ELEV), Compass Therapeutics (CMPX), and Poseida Therapeutics (PSTX). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals (NASDAQ:FENC) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.
Fennec Pharmaceuticals has higher earnings, but lower revenue than Coherus BioSciences. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.
Fennec Pharmaceuticals has a net margin of -75.50% compared to Coherus BioSciences' net margin of -92.48%.
55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 11.3% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 11.0% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Fennec Pharmaceuticals currently has a consensus target price of $17.33, suggesting a potential upside of 89.23%. Coherus BioSciences has a consensus target price of $9.29, suggesting a potential upside of 381.13%. Given Coherus BioSciences' higher possible upside, analysts plainly believe Coherus BioSciences is more favorable than Fennec Pharmaceuticals.
Fennec Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Coherus BioSciences received 244 more outperform votes than Fennec Pharmaceuticals when rated by MarketBeat users. However, 65.29% of users gave Fennec Pharmaceuticals an outperform vote while only 64.97% of users gave Coherus BioSciences an outperform vote.
In the previous week, Fennec Pharmaceuticals had 7 more articles in the media than Coherus BioSciences. MarketBeat recorded 8 mentions for Fennec Pharmaceuticals and 1 mentions for Coherus BioSciences. Fennec Pharmaceuticals' average media sentiment score of 0.34 beat Coherus BioSciences' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
Summary
Fennec Pharmaceuticals beats Coherus BioSciences on 9 of the 17 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
